IPO registrations (S-1, F-1) · Registrants
FEMASYS INC
- SEC CIK
- 1339005 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-05-14, last 2025-08-21; 3 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2021-06-21; declared effective 2021-06-17
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus 3841
- Incorporated in
- DE
- Business address
- 3950 JOHNS CREEK COURT, SUITE 100, Suwanee, GA 30024
- EIN
- 11-3713499
- Ticker
- FEMY (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- FEMASYS INC on the corporate pages
Offering terms
- Proposed price range
- $12.00–$14.00 per share (S-1/A filed 2021-06-14)
- Final price
- $13.00 per share, within the range (424B4 filed 2021-06-21, an initial public offering)
- Shares sold
- 2,650,000
- Gross proceeds
- $34,450,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol FEMY
- Lead underwriters
- Chardan
- Syndicate
- JonesTrading
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: FEMASYS INC. Fuzzy (name and state)
- Business registration: FEMASYS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: FEMASYS INC. EXACT (EIN (EXACT))
- Form D issuer: FEMASYS INC EXACT (CIK (EXACT))
- Lobbying client: FEMASYS INC. Fuzzy (name and state)
- SEC filer: FEMASYS INC EXACT (CIK (EXACT))
- Person page: Kathy Lee-Sepsick Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 15
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-05-14 | S-1 | S-1 (registration) | FEMASYS INC | 0001140361-21-017441 ↗ |
| 2021-06-14 | S-1/A | S-1/A (amendment) | FEMASYS INC | 0001140361-21-020726 ↗ |
| 2021-06-17 | EFFECT | EFFECT (declared effective) | FEMASYS INC | 9999999995-21-002390 ↗ |
| 2021-06-21 | 424B4 | 424B4 (final prospectus) | FEMASYS INC | 0001140361-21-021755 ↗ |
| 2022-07-12 | EFFECT | EFFECT (declared effective) | FEMASYS INC | 9999999995-22-002048 ↗ |
| 2023-06-23 | S-1 | S-1 (registration) | FEMASYS INC | 0001140361-23-031162 ↗ |
| 2023-07-07 | S-1/A | S-1/A (amendment) | FEMASYS INC | 0001140361-23-033752 ↗ |
| 2023-07-14 | EFFECT | EFFECT (declared effective) | FEMASYS INC | 9999999995-23-002094 ↗ |
| 2023-12-08 | EFFECT | EFFECT (declared effective) | FEMASYS INC | 9999999995-23-003583 ↗ |
| 2025-08-20 | S-1 | S-1 (registration) | FEMASYS INC | 0001140361-25-031990 ↗ |
| 2025-08-21 | S-1/A | S-1/A (amendment) | FEMASYS INC | 0001140361-25-032230 ↗ |
| 2025-08-25 | EFFECT | EFFECT (declared effective) | FEMASYS INC | 9999999995-25-002740 ↗ |
| 2025-12-09 | EFFECT | EFFECT (declared effective) | FEMASYS INC | 9999999995-25-003597 ↗ |
| 2026-01-09 | EFFECT | EFFECT (declared effective) | FEMASYS INC | 9999999995-26-000144 ↗ |
| 2026-09-28 | EFFECT | EFFECT (declared effective) | FEMASYS INC | 9999999995-26-003080 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-06-14 | S-1/A | registration statement | $12.00–$14.00 | $13.00 | 2,650,000 | $34,450,000 | Nasdaq FEMY | 2 | primary document; range, price sentence, shares headline, proceeds computed, cover names 2 | document ↗ |
| 2021-06-21 | 424B4 | final prospectus | $13.00 | 2,650,000 | $34,450,000 | Nasdaq FEMY | 2 | primary document; price sentence, shares headline, proceeds table, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Adams John Q JR | Director | 3 | 2021–2022 | ||
| Currie Daniel Scott | Officer | Chief Operating Officer; Senior VP, Operations | 6 | 2021–2025 | |
| Dyett John | Director; Director,TenPercentOwner | 4 | 2021–2022 | ||
| Kelley Hoskin Violet Alexandria | Officer | VP, Clinical & Medical Affairs | 1 | 2021 | |
| Larsen Charles | Director | 11 | 2021–2026 | ||
| Lee-Sepsick Kathy | Director,Officer | Chief Executive Officer | 10 | 2021–2026 | person page Fuzzy |
| Morrissey Anne | Director | 3 | 2021–2023 | ||
| Thompson Gary | Director; Officer | VP, Finance & Administration | 2 | 2021 | |
| Uzialko Edward R | Director; Director,TenPercentOwner | 7 | 2021–2026 | ||
| Witte William Benson | Director | 2 | 2021 | ||
| Evantash Edward | Officer | Chief Medical Officer | 1 | 2021 | |
| Perrow Wendy | Director | 4 | 2022–2023 | ||
| Elefant Dov | Officer | Chief Financial Officer | 11 | 2022–2026 | |
| Thomas Christine E | Officer | Chief Reg & Clinical Officer; SVP, Regulatory & Clinical | 5 | 2022–2025 | |
| Kendall Keith J | Director | 2 | 2023 | ||
| Milnes Alistair | Director | 5 | 2023–2026 | ||
| Silverman Joshua | Director | 5 | 2023–2026 | ||
| PharmaCyte Biotech, Inc. | TenPercentOwner | 2 | 2023–2026 | ||
| Spector Richard D. | Officer | Chief Commercial Officer | 2 | 2024 | |
| Nicholas Kelley Stinson | Officer | Chief Commercial Officer | 2 | 2025 | |
| Sipos Jeremy Alexander | Officer | Chief Technology Officer | 3 | 2026 | |
| Eichenbaum Kenneth D. | Director | 4 | 2026 | ||
| Canning John Charles | Officer | Chief Operating Officer | 3 | 2026 | |
| Mifek Jeffrey Gerald | Officer | Chief Clinical-Medical Affairs | 3 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-08-20 | FEMASYS INC | Biotechnology | $30,000,000 | $30,000,000 | 41 | 1 |
| 2025-11-14 | FEMASYS INC | Biotechnology | $12,000,000 | $8,025,000 | 12 | 1 |
| 2025-06-10 | FEMASYS INC | Biotechnology | $1,450,000 | $1,450,000 | 6 | 1 |
| 2023-11-22 | FEMASYS INC | Biotechnology | $6,850,000 | $6,850,000 | 4 | 1 |
| 2017-01-13 | FEMASYS INC | Biotechnology | $4,000,000 | $4,000,000 | 8 | 1 |
| 2016-12-27 | FEMASYS INC | Biotechnology | $36,628,704 | $36,628,704 | 18 | 1 |
| 2016-08-11 | FEMASYS INC | Biotechnology | $4,000,000 | $3,296,700 | 19 | 1 |
| 2015-04-28 | FEMASYS INC | Other Health Care | $8,000,000 | $8,000,000 | 3 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | FEMASYS INC | GA | Form D private offerings | CIK (EXACT) |
| IPO registrant | TOWNE SERVICES INC | GA | IPO registrations (S-1, F-1) | same street address and ZIP code, 3950 JOHNS CREEK CT STE 100 30024 (FUZZY: a shared address, not proof of a shared organization) |
| SEC filer | FEMASYS INC | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | FEMASYS INC. | State business registries | name and state | |
| Business registration | FEMASYS, INC. | State business registries | name and state | |
| Form 5500 plan sponsor | FEMASYS INC. | EIN (EXACT) | ||
| Lobbying client | FEMASYS INC. | Federal lobbying (LDA) | name and state | |
| Person page | Kathy Lee-Sepsick | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Surgical & Medical Instruments & Apparatus, GA first:
- CARDIOMEMS INC GA
- EndoChoice Holdings, Inc. GA
- MIV THERAPEUTICS INC A1
- BIOCUREX INC A1
- Enox Biopharma Inc A1
- Stimcell Energetics Inc. A1
- EVOME MEDICAL TECHNOLOGIES INC. A1
- Breathe BioMedical Inc. A3
- LEGACY VENTURES INTERNATIONAL INC. A6
- TITAN MEDICAL INC A6
In other datasets, the same topic (Technology) in GA:
- Form D issuer: 2080 MEDIA INC (Form D private offerings)
- Lobbying client: 7P CONSULTING LLC (Federal lobbying (LDA))
Interests: Surgical & Medical Instruments & Apparatus · Technology